Search Results

Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022.

Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc.

Otonomy, Inc. reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities.

Otonomy, Inc. announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Otonomy, Inc. announced that management will participate in the following virtual investor conference events.

Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced its participation in the H.C. Wainwright Global Investment Conference.

Otonomy, Inc. today announced that the clinical evaluation of higher doses for OTO-413 (0.75 mg and 1.50 mg) in patients with hearing loss demonstrated no clinically meaningful improvement for patients from baseline across multiple speech-in-noise (SIN) hearing tests.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended June 30, 2022 and provided an update on its product pipeline and corporate activities.